|
|
11 Studebaker
Irvine, CA 92618 USA
phone:949.595.7200
fax:949.457.9561
|
|
| Symbol |
ELGX |
| Exchange |
Nasdaq |
| Founded |
1992 |
| Employees |
168 |
|
|
| www.endologix.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Catheter-based alternative to surgery for treating abdominal aortic aneurysms. |
|
| Management |
| John McDermott, President and Chief Executive Officer; Joseph A. DeJohn, Vice President Sales; Janet Fauls, Vice President of Regulatory and Clinical Affairs; Daniel Hawkins, Vice President of Global Marketing; Robert J. Krist, Chief Financial Officer and Secretary |
| |
|
|
|
|
|
|
|
| Keywords |
| vascular, aneurysm, endoluminal, femoral, abdominal |
|
|
|
| Description |
|
Endologix develops, manufactures and markets minimally invasive treatments for vascular diseases, including the Powerlink System for the treatment of abdominal aortic aneurysms (AAA). |
|
| Products / Services |
The PMA-approved Powerlink System has an innovative design with significant advantages compared with alternative devices for AAA treatment. It consists of a self-expanding stainless steel stent cage covered with ePTFE, a common surgical graft material. The Powerlink Stent Graft is offered in various configurations to meet different needs: Infrarenal Bifurcated, Suprarenal Bifurcated and Aorto Uni-iliac. Visiflex is Endologix's next generation product, providing improved catheter flexibility and device delivery.
|
|
| Technology / Differentiation |
| The one-piece design of Powerlink's stent graft enables placement of the device on the aortic bifurcation, providing anatomical fixation and excellent long-term clinical outcomes. Endologix's proprietary technologies, the Cobalt-Chromium Stent and High-Density ePTFE, are designed to expand in vivo to reline the aorta and isolate the aneurysm; the combination of fatigue-resistant cobalt-chromium alloy and high-density ePTFE provide a durable, long-term implant. The company's proprietary SurePass guidewire technology establishes and maintains guidewire access during a procedure. Competitive AAA devices often require time-consuming guidewire manipulations to assemble components, while SurePass eliminates extraneous steps and reduces procedure time. Finally, the low-profile Powerlink Delivery System requires only a small incision in one leg, whereas other AAA devices typically require surgical incisions in both legs to introduce multiple components. This unique design enables the Powerlink System to be used in patients with limited or difficult vascular access. |
|
| Market / Customers |
Each year, approximately 200,000 abdominal aortic aneurysm (AAA) are diagnosed in the United States, and roughly 60,000 patients undergo surgery. AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the 13th leading cause of death in the United States.
|
|
| Competitors / Substitutes / Alternatives |
Medtronic, W.L. Gore, Cook
|
|
| Status |
| In May 2008, John McDermott was named President and Chief Executive Officer, bringing nearly 20 years of executive management, sales, marketing and finance experience in the vascular device industry. The company also appointed an industry veteran as Vice President of Sales in July 2008. Management is focused on revenue growth and continued market share gains from sales execution, marketing and new product launches. Endologix, Inc. announced that for the fourth quarter of 2008, it expects global sales of at least $10 million, which represents fiscal 2008 sales growth of at least 38% over fiscal 2007. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members